Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("Company" or "Kraig Labs"), a world leader in spider silk technology*, today announced the successful completion of its first simultaneous production ...

IPN10200 is a recombinant, first-in-class molecule uniquely engineered to generate increased receptor affinity and internalization that produces ...

Thrombocytopenia following myelotoxic therapy is a common problem and can lead to substantial morbidity and mortality when severe (<10 000–20 000/μl). Other detrimental events such as transfusion ...

Endotoxin testing is critical for quality control in drug production, as it has a direct impact on pharmaceutical safety and effectiveness. Traditionally Limulus Amebocyte Lysate (LAL) testing is used ...

An investor asked Shanghai Raas on the Shenzhen Stock Exchange interactive platform: "Hello, Secretary of the Board! How is your company's new product research and production situation? Thank you!" ...

Treatment of patients at high risk for developing OM with low- or high-dose rhITF significantly reduced the amount of incidence (75% to 81%; low-dose rhITF P < .001; high-dose rhITF P = .002).

The production of vaccines, monoclonal antibodies, and recombinant proteins relies on mammalian cell cultures, which are vulnerable to contamination by retroviruses such as murine leukemia virus and ...

The use of recombinant activated factor VII (rFVIIa) on an off-label basis to treat life-threatening bleeding has been associated with a perceived increased risk of thromboembolic complications.

Recombinant DNA (rDNA) has many uses in the society of today, from research and biotechnology to the medicine stocked on the shelves of pharmacies. The ability to manipulate the creation of DNA with ...

Previous research has shown the recombinant zoster vaccine is more effective than its live-attenuated predecessor, but new ...

SOUTH SAN FRANCISCO, Calif., Sept. 19, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT) (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing a range of oral recombinant ...